Kiniksa Pharmaceuticals International (KNSA) Short-term Investments (2017 - 2026)

Kiniksa Pharmaceuticals International (KNSA) has reported Short-term Investments for 10 consecutive years, with $350.3 million the latest figure, recorded in Q2 2026.

• For the quarter ending Q2 2026, Short-term Investments rose 202.61% year-over-year to $350.3 million; the trailing twelve-month figure through Jun 2026 stood at $350.3 million (up 202.61% YoY), and the FY2025 full-year result was $248.5 million, up 313.81% from the prior year.
• Short-term Investments climbed to $350.3 million in Q2 2026 per KNSA's latest filing, from $278.1 million in the prior quarter.
• Across five years, Short-term Investments topped out at $350.3 million in Q2 2026 and bottomed at $60.0 million in Q4 2024.
• Historically, Short-term Investments has averaged $141.5 million across 5 years, with a median of $113.5 million in 2025.
• The sharpest annual moves came in 2024 and 2025: Short-term Investments sank 38.99% in 2024, then jumped 313.81% in 2025.
• Over 5 years, Short-term Investments stood at $67.9 million in 2022, then jumped by 44.96% to $98.4 million in 2023, then slumped by 38.99% to $60.0 million in 2024, then surged by 313.81% to $248.5 million in 2025, then surged by 40.96% to $350.3 million in 2026.
• According to Business Quant data, Short-term Investments over the past three periods registered $350.3 million, $278.1 million, and $248.5 million for Q2 2026, Q1 2026, and Q4 2025 respectively.